Stay updated with breaking news from Pharmabbie inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BDA is pleased to announce that Mutares SE & Co. KGaA (“Mutares”), a listed private equity holding company, has successfully completed the sale of its 73.25% stake in STS Group AG (“STS”). STS develops, manufactures and supplies interior & exterior components made of. - July 05, 2021 - BDA Partners Ltd BDA Partners is pleased to announce that it has advised Navis Capital on the sale of Amazon Papyrus Chemicals Group to The Longreach Group. Terms of the transaction were not disclosed. BDA Partners was the exclusive financial advisor to Navis Capital and Amazon Papyrus on the transaction. BDA also. - July 05, 2021 - BDA Partners Ltd ....
PharmAbbie, Inc. Announces the Launch of a Reg D-506(c) Common Stock Offering Groton, CT, June 09, 2021 (PR.com) PharmAbbie, Inc. is pleased to announce today that it will offer up to 3,191,489 shares of its Class D Common Stock at an offering price of $4.70 per share for an aggregate offering amount of $15,000,000. The shares will be offered to accredited investors only pursuant to Regulation D, Rule 506(c) under the Securities Act of 1933, as amended (the “Security Act”). Purchasers are required to verify their “accredited investor” status. Incorporated in Delaware and located in Groton, Connecticut, PharmAbbie, Inc. is a late-stage companion animal pharmaceutical development company with six products in various stages of regulatory approval at the United States Food and Drug Administration’s Center for Veterinary Medicine (“FDA-CVM”). PharmAbbie focuses on four therapeutic areas, representing more than half of all veterinary prescriptions: pain and inf ....